PARTICIPANTS NOT ON THE HODGKIN LYMPHOMA EXPANSION COHORT: Platelets >= 75,000/mm^3, within 2 weeks prior to enrollmentXx_NEWLINE_xXPlatelets >= 75,000/mcL, within 2 weeks of randomizationXx_NEWLINE_xXPlatelets >= 75 x 10^9/L within 30 days of day 1 of studyXx_NEWLINE_xXPlatelets >= 75,000/uL unless related to bone marrow involvement by HIV-cHLXx_NEWLINE_xXWithin 28 days prior to registration: Platelets >= 75,000/mcLXx_NEWLINE_xXSTEP I: Untransfused platelet count >= 75,000 cells/mm^3 (obtained within 28 days prior to randomization)Xx_NEWLINE_xXSTEP II: Platelet count >= 75,000 cells/mm^3 (within 28 days prior to randomization to Step II)Xx_NEWLINE_xXPlatelets >= 75,000/mcL within 14 days prior to step 2 randomizationXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mcL; must be obtained within 28 days prior to registrationXx_NEWLINE_xXPlatelet count >= 100,000 mm^3; platelets >= 75,000 required for patients who received cycle 1 of mFOLFOX6 prior to registrationXx_NEWLINE_xXWithin 14 days of registration: Platelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/mcL within 28 days prior to registrationXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXRegistration Step 3 – Maintenance: Patients must have adequate marrow function as evidenced by platelets >= 75,000/mcl within 28 days prior to registrationXx_NEWLINE_xXPlatelets >= 75,000 g/uLXx_NEWLINE_xXPlatelets (Plts) greater than or equal to 75,000/mm^3 (transfusion independent)Xx_NEWLINE_xXPlatelet count ? 75 x 10^9/L (75,000/mm3)Xx_NEWLINE_xXPlatelet count ? 75,000/mm3Xx_NEWLINE_xXPlatelet count >= 75,000/ mm^3 (=< 28 days prior to registration)Xx_NEWLINE_xXPlatelet count ? 75,000 cells/mm3 (75 x 109/L)Xx_NEWLINE_xXINCLUSION CRITERIA FOR SECOND-LINE THERAPY: Platelets >= 75,000/mm^3Xx_NEWLINE_xXINCLUSION CRITERIA FOR THIRD-LINE THERAPY: Platelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/uL (transfusion independent for >= 7 days)Xx_NEWLINE_xXPlatelets ?75,000 µLXx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets greater than or equal to 75,000/ulXx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/?L (unless documented bone marrow involvement with lymphoma)Xx_NEWLINE_xXPlatelet count (PLT) > 75,000/µLXx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/ulXx_NEWLINE_xXPlatelet count ? 75,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelets ? 75,000/ulXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcL (>= 30,000 if there is bone marrow involvement with lymphoma)Xx_NEWLINE_xXPlatelet count ? 75,000 (platelets/?L)Xx_NEWLINE_xXPlatelet count ? 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/mcL, unless due to marrow involvement by lymphoma in which case a platelet count of >= 30,000/mcL will be usedXx_NEWLINE_xXDocumented within 14 days of registration: Platelets >= 75,000/ul (unsupported)Xx_NEWLINE_xXPlatelets ? 75 x 10^9/L Chemistry:Xx_NEWLINE_xXPlatelets ?75,000/mm3 without platelet transfusion ? 3 days prior to C1D1Xx_NEWLINE_xXPlatelet count ? 75,000/uL\r\n* The above criteria do not have to be met if the patient has bone marrow involvement of tumorXx_NEWLINE_xXPlatelet count >= 75,000/mm^3; in the case that platelets are between 50,000 -75,000, the patient can be enrolled if the plasma cell count in the bone marrow is superior to >= 50%; to meet this hematological eligibility no transfusion support and hematological growth factor are not allowed within 7 days before study enrollmentXx_NEWLINE_xXPlatelets >= 75 x 10^9/L, at the screening visitXx_NEWLINE_xXPlatelet count >= 75,000/mcLXx_NEWLINE_xXPlatelets ? 75,000/?LXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000 cells /uL (unsupported, defined as no platelet transfusion within 7 days)Xx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Platelets >= 75,000 cells/uL (unsupported, defined as no platelet transfusion within 7 days)Xx_NEWLINE_xXPlatelet count > 75,000 cells/mm^3 (75 x 10^9/L), if thrombocytopenia is due to bone marrow involvement platelet count must be >= 50,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelet count >= 75,000 and transfusion independentXx_NEWLINE_xXPlatelet count < 75,000/uLXx_NEWLINE_xXPlatelet (PLT) > 75,000Xx_NEWLINE_xXPlatelets ?75 x 109/LXx_NEWLINE_xXPlatelets >= 75,000 totalXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/uL (transfusion independent)Xx_NEWLINE_xXPART I: Platelet count >= 75,000/mm^3Xx_NEWLINE_xXPART II: Platelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000 K/uLXx_NEWLINE_xXPlatelets >= 75 K/uLXx_NEWLINE_xXPlatelets >= 75,000/mm^3 (100 x 10^9/L)Xx_NEWLINE_xXPlatelets >= 75,000Xx_NEWLINE_xXPerformed within 10 business days of treatment initiation with the exception of beta- HCG (72 hours), if applicable: Platelets >= 75,000 / uL.Xx_NEWLINE_xXPlatelets >= 75,000 per mm^3 obtained within 14 days prior to initiating study treatment.Xx_NEWLINE_xXPlatelets < 75,000 cell/mm^3 (75 x 10^9/L). Qualifying laboratory value must occur at most recent measurement before enrollment and must be no more than 14 days before enrollment. No transfusions are allowed within 72 hours prior to study drug administrationXx_NEWLINE_xXPlatelets ? 75,000/mclXx_NEWLINE_xXPlatelets ? 75,000/microliterXx_NEWLINE_xXPlatelet count ? 75,000 cells/mm3 (75 x 109/L) (without required transfusions during the 10 days prior to initiation of therapy)Xx_NEWLINE_xXPlatelet count ?75,000/?LXx_NEWLINE_xXPlatelets >= 50,000/mm^3 for MCL cohort and platelets >= 75,000/mm^3 for DLBCL cohort, performed within 14 days prior to day 1 of protocol therapy\r\n* NOTE: platelet transfusions and packed red blood cell transfusion can be given prior to enrollment to achieve a target platelet (Plt) >= 50,000/uL for MCL and >= 75,000/uL for DLBCL and hemoglobin of >= 8.5 g/dLXx_NEWLINE_xXPlatelets at least 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcL.Xx_NEWLINE_xXPlatelets >= 75,000/microliterXx_NEWLINE_xXPlatelet count (PLT) >= 75,000/mm^3 (measured within 28 days of registration)Xx_NEWLINE_xXPlatelets ? 75,000/mcLXx_NEWLINE_xXObtained within 21 days prior to cycle 1, day 1: platelet count >= 75,000/mm3Xx_NEWLINE_xXPlatelet >= 75,000/uLXx_NEWLINE_xXWithin 28 days of cycle 1 day 1: Platelets >= 75,000/mcLXx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Platelet count >= 75,000/mm^3 (>= 75 X 10^6/L)Xx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Platelet count >= 75,000/mm^3 (>= 75 X 10^6/L)Xx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Platelet count >= 75,000/mm^3 (>= 75 X 10^6/L)Xx_NEWLINE_xXPlatelets >= 75,000/ uL, within 2 weeks of registrationXx_NEWLINE_xXPlatelets >= 75,000 cells/uLXx_NEWLINE_xXPlatelets ?75,000/mm³Xx_NEWLINE_xXWithin two weeks prior to enrollment: Platelets >= 75,000/mcL and > 7 days since last platelet transfusionXx_NEWLINE_xXPlatelet count >= 75,000/mm^3 within 90 days prior to randomizationXx_NEWLINE_xXPlatelets >= 75,000/uL, if plasma cell percentage on bone marrow biopsy aspirate or core is > 30%, platelet eligibility requirement will be adjusted to 60,000/ulXx_NEWLINE_xXWithin 14 days of the first dose of the study drugs: Platelets >= 75,000/L.Xx_NEWLINE_xXPlatelet count > 75,000/uL unless disease-related (due to marrow infiltration or splenomegaly)Xx_NEWLINE_xXPlatelets ? 75,000/mm^3 within 10 days prior to “on study” statusXx_NEWLINE_xXAge >75.Xx_NEWLINE_xXPlatelet count >= 75 x 10^9/L (> 75,000 per mm^3)Xx_NEWLINE_xXPlatelet count >= 75,000 cells/mm^3 (75 x 10^9/L) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1Xx_NEWLINE_xXWithin 14 days prior to registration: Platelets >= 75,000/mclXx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mcL (unless dysfunction is secondary to lymphoma involvement)Xx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelet count > 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/ LXx_NEWLINE_xXPlatelet count greater than 75,000/mm^3Xx_NEWLINE_xXPlatelet count < 75,000 mm3 without transfusion support within 7 days prior to testingXx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXObtained within 14 days prior to enrollment: platelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcL, performed within 14 days of protocol registrationXx_NEWLINE_xXPlatelets ? 75,000/µlXx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelets (PLT) ? 75,000 cells/mm3Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets ? 75 x 109/LXx_NEWLINE_xXPlatelets >= 75,000Xx_NEWLINE_xXDetermined within 3 weeks of treatment initiation: Platelet count >= 75,000/mm^3 (75 x 10^9/L)Xx_NEWLINE_xXPlatelet count > 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelets >= 75,000/mm^3 (transfusions not permitted within 7 days of screening)Xx_NEWLINE_xXPlatelets >= 75 X 10^9/LXx_NEWLINE_xXPlatelet count >= 75,000/mm^3 (obtained =< 14 days prior to registration)\r\n* Criteria must be met without a transfusion within four weeks of registrationXx_NEWLINE_xXPlatelet count >= 75,000/uL, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)Xx_NEWLINE_xXPlatelet ? 75,000/uLXx_NEWLINE_xXPlatelets: >= 75,000/mm^3, unless decreased due to bone marrow involvement with lymphomaXx_NEWLINE_xXPlatelet count ?75,000/uLXx_NEWLINE_xXPlatelets >= 75,000 per microliterXx_NEWLINE_xXPlatelet (Plt) >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count >= 75 x 10^9/L (>= 75,000 per mm^3)Xx_NEWLINE_xXPlatelet >= 75,000/mm^3\r\n*Unless related to bone marrow involvement with disease, in which case platelets must be >= 50,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mcL (without transfusion support)Xx_NEWLINE_xXPlatelets >= 75 K/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75 x 10^3/uL should be obtained within 21 days prior to enrollmentXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/uL at screening visitXx_NEWLINE_xXPlatelets >= 75,000/uL at screening visitXx_NEWLINE_xXPlatelet count >= 75,000/mm^3 (>= 75 X 10^6/L)Xx_NEWLINE_xXPlatelet count > 75,000 cells/mm^3 (75 x 10^9/L)Xx_NEWLINE_xXPlatelets > 75,000/uLXx_NEWLINE_xXPlatelet count >= 75,000 (platelets [plt]/mm^3), (CTCAE grade 1 baseline)Xx_NEWLINE_xXPlatelets >= 75,000 cells/uLXx_NEWLINE_xXPlatelet count (PLT) >= 75,000/uL obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelets < 75,000/mm^3 unless lymphoma, KSHV-MCD, or KICS-relatedXx_NEWLINE_xXPlatelet count < 75,000/mlXx_NEWLINE_xXPlatelets >= 75,000Xx_NEWLINE_xXPlatelets >= 75,000/dLXx_NEWLINE_xXPlatelets > 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets < 75,000/mm^3 (SI units 109/L)Xx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelets > 75,000/LXx_NEWLINE_xXPlatelets >= 75,000/mcl (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment)Xx_NEWLINE_xXPlatelet count >= 75,000/ul (unless documented bone marrow involvement with lymphoma)Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets < 75,000/mm^3 [75 x 10^9/L]Xx_NEWLINE_xXEXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Platelet count < 75,000/mm^3Xx_NEWLINE_xXEXCLUSION CRITERIA FOR TNBC: Platelet count < 75,000/mm^3Xx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: Platelet count > 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets > 75,000/mcLXx_NEWLINE_xXPlatelets < 75,000/mm^3 (75 x 10^9/L)Xx_NEWLINE_xXPlatelets < 75,000 cell/mm^3 (75 x 10^9/L); qualifying laboratory value must occur at most recent measurement before enrollment and must be no more than 14 days before enrollment; no transfusions are allowed within 72 hours before qualifying laboratory valueXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count (transfusion independent) >= 75,000/mm^3Xx_NEWLINE_xXPlatelets (PLT) >= 75 x 10^9/L without transfusionsXx_NEWLINE_xXPlatelets >= 75,000/mm^3 without platelet transfusion =< 7 days prior to C1D1Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Platelets >= 75,000/mcLXx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Platelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcl (without transfusion for 7 days).Xx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlts ? 75,000 - cannot be transfused (must be ? 7 days from last plt transfusion)Xx_NEWLINE_xXPlatelet count < 75,000/uLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3, obtained =< 7 days prior to registrationXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets ? 75,000/?LXx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count ? 75,000/µLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count ? 75,000/mm3;Xx_NEWLINE_xXPlatelets greater than or equal to 75,000/mm^3 (transfusion independent; no transfusion for >= 7 days prior to study enrollment)Xx_NEWLINE_xXPlatelet count ? 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mclXx_NEWLINE_xXPlatelets > 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mcL (without transfusion support)Xx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count < 75 K/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet (PLT) >= 75,000/uL, obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelets >= 75 KXx_NEWLINE_xXPlatelets >= 75 k/uLXx_NEWLINE_xXWithin 30 days of first vaccination: Platelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet >= 75,000/uLXx_NEWLINE_xXPlatelet count < 75,000/mm3Xx_NEWLINE_xXPlatelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelets > 75 x 10^9/LXx_NEWLINE_xXPlatelets >= 75,000/mcL (75 x 10^9/L) obtained within 2 weeks prior to registrationXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): Platelets >= 75,000/mcL (75 x 10^9/L), obtained within 2 weeks prior to registrationXx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelet (Plt) >= 75,000Xx_NEWLINE_xXPlatelets > 75,000, unless due to direct bone marrow involvement of diseaseXx_NEWLINE_xXPlatelets >= 75,000/uL (within 2 weeks prior to radiotherapy)Xx_NEWLINE_xXPlatelet count ? 75,000/mm3Xx_NEWLINE_xXPlatelets (Plt) >= 75,000Xx_NEWLINE_xXPlatelets >= 75,000/mm^3, within 14 days prior to study entryXx_NEWLINE_xXPlatelets >= 75,000/mLXx_NEWLINE_xXPlatelets >= 75,000/mLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets > 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3 obtained =< 14 days prior to registrationXx_NEWLINE_xXPlatelets =< 75,000/ulXx_NEWLINE_xXPlatelets (Plts) greater than or equal to 75,000/mm^3 (transfusion independent)Xx_NEWLINE_xXPlatelet count > 75,000Xx_NEWLINE_xXPlatelet > 75,000/uLXx_NEWLINE_xXPlatelet >= 75,000/mm^3 (unless impairment due to idiopathic thrombocytopenic purpura [ITP])Xx_NEWLINE_xXPlatelet count ?75,000/mm3.Xx_NEWLINE_xXPlatelets >= 75,000 K/CUMMXx_NEWLINE_xXPlatelet count must be greater than or equal to 75,000/mm3; andXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count ? 30,000/mm3 (75 x 109/L)Xx_NEWLINE_xXPlatelets ? 75 x 109 cells/LXx_NEWLINE_xXPlatelets > 75,000, unless due to direct bone marrow involvement of diseaseXx_NEWLINE_xXPlatelet count greater than 75,000/mm³Xx_NEWLINE_xXPlatelets (plt) ? 100 x 10^9/L for paclitaxel cohort, and ? 75, 000 for endocrine therapy cohortXx_NEWLINE_xXPlatelet count >= 75,000 /mm^3 within 28 days prior to registration.Xx_NEWLINE_xXWithin 14 days prior to day 1 of protocol therapy unless otherwise stated: Platelets >= 75,000/mm^3\r\n* NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvementXx_NEWLINE_xXPlatelets >= 75,000/mclXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets less than or equal to 75,000Xx_NEWLINE_xXEXCLUSION CRITERIA FOR TREATMENT: Platelets less than or equal to 75,000Xx_NEWLINE_xXPlatelet >= 75,000/µLXx_NEWLINE_xXTo be performed within 28 days prior to day 1 of protocol therapy: Platelets >= 75,000/mm^3 without transfusionsXx_NEWLINE_xXPlatelet count >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mclXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count >= 75,000 /mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count greater than 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000 cells/uLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count must be >= 75,000/mm^3 (not achieved by transfusion) unless due to underlying disease in which case there is no grade restrictionXx_NEWLINE_xXPlatelet count >= 75,000/uLXx_NEWLINE_xXPlatelets (PLT) >= 75,000 cells/mm^3 for 5 days after recovery from ASCT nadirXx_NEWLINE_xXObtained within 28 days prior to registration: Platelets >= 75,000/mcLXx_NEWLINE_xXPlatelets greater than or equal to 75,000/ulXx_NEWLINE_xXPlatelets ?75,000/mm3Xx_NEWLINE_xXPlatelet >= 75,000/uLXx_NEWLINE_xXPlatelets > 75,000/uLXx_NEWLINE_xXPlatelet count ? 75,000/µLXx_NEWLINE_xXPlatelet count ?75,000 (plt/mm3) (CTCAE Grade 1 baseline)Xx_NEWLINE_xXUntransfused platelet count < 75,000 cells/?LXx_NEWLINE_xXPlatelets ?75,000/mm3 (?75 × 10^9/L)Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets < 75,000Xx_NEWLINE_xXPlatelets ? 75 x10?/LXx_NEWLINE_xXPlatelet count ? 75,000 cells/dL (75 x 109/L)Xx_NEWLINE_xXPatients in CRi must have evidence of hematologic recovery after prior therapy to at least: platelets >= 75 x 10^9/LXx_NEWLINE_xXPlts > 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelets ? 75,000/mm3 (unsupported for 7 days)Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets (PLT) <75 x 109/L (75x103/µL)Xx_NEWLINE_xXPlatelets >= 75 x 10^9/L (no platelet transfusion within past 14 days)Xx_NEWLINE_xXPlatelets ? 75 x 103/?LXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count > 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/ulXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count < 75,000Xx_NEWLINE_xXPlatelet count >= 75,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/microliterXx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3 (75 x 10^9/L)Xx_NEWLINE_xXPlatelet count > 75,000/uLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3 obtained =< 7 days prior to registrationXx_NEWLINE_xXPlatelets > 75,000/µlXx_NEWLINE_xXPlatelet count ? 75 x 10^9/L (75,000/mm3)Xx_NEWLINE_xXPlatelets (PLT) > 75,000/ulXx_NEWLINE_xXPlatelet count less than 75,000Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelet count > 75,000/?LXx_NEWLINE_xXPlatelet count >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelet count (PLT) >= 75,000 /uL without transfusions obtained =< 7 days prior to registrationXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count ? 75,000/ µLXx_NEWLINE_xXPlatelets ? 75,000/?LXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelets >= 75,000/uL, if plasma cell percentage on bone marrow biopsy aspirate or core is > 30%, platelet eligibility requirement will be adjusted to 60,000/uLXx_NEWLINE_xXPlatelets ? 75 × 109/L.Xx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXCOHORT A: Platelets >= 75 x 10^3/uLXx_NEWLINE_xXCOHORT B: Platelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelet count < 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets > 75,000/uLXx_NEWLINE_xXObtained within 14 days prior to the first study treatment (cycle 1, day 1); platelet count ? 75,000/uLXx_NEWLINE_xXPlatelet count > 75,000 cells/mm^3 (75 x 10^9/L), if thrombocytopenia is due to bone marrow involvement platelet count must be 50,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXUntransfused platelet count >= 75,000/uLXx_NEWLINE_xXPlatelet count >= 75,000/m^3 (no transfusion within 7 days of enrollment)Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count greater than or equal 75 x 10^9/L (greater than or equal 75,000/mm^3)Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets > 75,000/mcLXx_NEWLINE_xXPlatelets (Plt) >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelet count > 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelets > 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelets < 75 x 10^9/LXx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000 per uLXx_NEWLINE_xXPlatelets greater than 75,000/mm^3Xx_NEWLINE_xXLow platelets (< 75 k/ul)Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets > 75,000/uLXx_NEWLINE_xXPlatelet count >= 75,000/ulXx_NEWLINE_xXPlatelets >= 75,000/uL (unless significant bone marrow involvement with MCL)Xx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count > 75,000/mm^3Xx_NEWLINE_xXPlatelet count > = 75,000 /mm³Xx_NEWLINE_xXPlatelets (PLT) >= 75,000/ulXx_NEWLINE_xXPlatelet count >= 75,000, unless due to underlying lymphomaXx_NEWLINE_xXPlatelets: >= 75 x 10^3/uL (~ 75 x 10^9/L)Xx_NEWLINE_xXPlatelet count greater than 75,000/mm^3Xx_NEWLINE_xXPlatelet count greater than or equal to 75,000/mcLXx_NEWLINE_xXPlatelet (PLT) >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/ulXx_NEWLINE_xXSORAFENIB ARM: platelets >= 75,000/mLXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count ?75 x 109/L (?75,000/mm3)Xx_NEWLINE_xXPlatelets ? 75,000/?L (without intervention, e.g., transfusion)Xx_NEWLINE_xXPlatelet >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count ? 75,000/mm3 Arms B, C, and D must meet the following criteria:Xx_NEWLINE_xXPlatelet count ? 75,000/mm3Xx_NEWLINE_xXPlatelets > 75,000/mm^3Xx_NEWLINE_xXPlatelets (PLT) >= 75,000/uL obtained =< 14 days prior to registration with no platelet transfusion requirement for 7 days prior to enrollmentXx_NEWLINE_xXPlatelets > 75,000 unless impairment due to organ involvement by lymphomaXx_NEWLINE_xXPlatelets > 75,000 cells/ulXx_NEWLINE_xXPlatelets of at least 75,000 x 106/LXx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3 (unsupported)Xx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000 unless cytopenias are related to bone marrow involvement with diseaseXx_NEWLINE_xXPlatelets >= 75,000Xx_NEWLINE_xXPlatelets: >= 75 x 10^3/uL (~75 x 10^9/L)Xx_NEWLINE_xXPlatelet count > 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelet count must be >= 75,000/mm^3 (not achieved by transfusion)Xx_NEWLINE_xXPlatelet count >= 75,000/ulXx_NEWLINE_xXPlatelets <75,000/?LXx_NEWLINE_xXPlatelets >= 75,000/mclXx_NEWLINE_xXPlatelets >= 75 K/uL (transfusions are permissible)Xx_NEWLINE_xXPlatelet count <75,000/mLXx_NEWLINE_xXPlatelet >= 75,000 cells/mm^3, +/- 7 days from date of ICF signingXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelet count ? 75,000/uLXx_NEWLINE_xXPlatelet count ?75,000/mm³Xx_NEWLINE_xXPlatelet count (Plt) >= 75,000/uLXx_NEWLINE_xXPlatelets: >= 75,000/ulXx_NEWLINE_xXPlatelet count > 75,000/ ul 3Xx_NEWLINE_xXPlatelet count >= 75,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelets ?75,000 /mLXx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelet >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelet count >= 75,000/ mm^3 (transfusion independent for > 7 days)Xx_NEWLINE_xXPlatelets ? 75,000 /mL;Xx_NEWLINE_xXPlatelet count > 75,000 mm^3Xx_NEWLINE_xXPlatelets >= 75,000Xx_NEWLINE_xXPlatelets >= 75,000/mcL (unless due to lymphoma involvement of the bone marrow)Xx_NEWLINE_xXPlatelet count < 75,000 mm3 without transfusion support within 7 days prior to testingXx_NEWLINE_xXPlatelet count >= 75,000/uL (transfusion independent)Xx_NEWLINE_xXPlatelets > 75 x 10^9/LXx_NEWLINE_xXPlatelets >= 75,000/uL, unless due to bone marrow involvement by lymphomaXx_NEWLINE_xXPlatelet count ?75,000/µlXx_NEWLINE_xXPlatelet count > 75,000/mm^3Xx_NEWLINE_xXPlatelet count >= 75,000/?LXx_NEWLINE_xXPlatelet count >= 75,000/uLXx_NEWLINE_xXPlatelets ? 75 x 109/L without transfusions within 21 days before 1st treatment.Xx_NEWLINE_xXPlatelet count < 75,000/mlXx_NEWLINE_xXPlt > 75 K/ml (without transfusion)Xx_NEWLINE_xXPlatelet (PLT) count ? 75,000/microliterXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPeripheral platelet count (PLT) >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/mm^3Xx_NEWLINE_xXPlatelets < 75,000/ microliterXx_NEWLINE_xXPlatelets ? 75,000 cells/mm^3 (75 × 10^9/L), without platelet transfusion, within 72 hours of screening evaluation.Xx_NEWLINE_xXPlatelets > 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets (PLT) >= 75,000/uLXx_NEWLINE_xXPlatelets < 75,000/mm^3 (SI units 109/L)Xx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75 x 10^3/uLXx_NEWLINE_xXPlatelets >= 75,000Xx_NEWLINE_xXPlatelets >= 75,000 cells/mm^3Xx_NEWLINE_xXPlatelets >= 75,000/?L unless due to marrow involvement by lymphomaXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/mcLXx_NEWLINE_xXPlatelets >= 75,000/uL and transfusion independent, defined as not receiving a platelet transfusion for at least 5 days prior to complete blood count (CBC) documenting eligibilityXx_NEWLINE_xXPlatelets ? 75,000 cells/mm3Xx_NEWLINE_xXPlatelet count ? 75x109/L (75,000/uL) without transfusionXx_NEWLINE_xXPlatelets >= 75,000/mm^3 (>= 75 x 10^9/L)Xx_NEWLINE_xXPlatelets >= 75 x 10^9/L and no platelet transfusion within the past 21 days prior to study registrationXx_NEWLINE_xXPlatelets >= 75 K/mm^3Xx_NEWLINE_xXPlatelets: >= 75,000/mm^3 within 90 days before enrollmentXx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets ? 75,000/?LXx_NEWLINE_xXPlatelet count >= 75,000/mm^3 within 90 days of enrollmentXx_NEWLINE_xXPlatelets >= 75,000 / uLXx_NEWLINE_xXStable platelet count >= 75,000/mm^3 (>= 75 k/uL)Xx_NEWLINE_xXPlatelets >= 75 x 10^9/LXx_NEWLINE_xXPlatelets ? 75 x 10?/LXx_NEWLINE_xXPlatelets (plt) ? 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000/uLXx_NEWLINE_xXPlatelets >= 75,000 cells/uLXx_NEWLINE_xXPlatelets >= 75 K/mcLXx_NEWLINE_xXPlatelet count >75,000/ mm3Xx_NEWLINE_xXPlatelets < 75 K/mcLXx_NEWLINE_xXPlatelets >= 75,000 cells/uLXx_NEWLINE_xXUnacceptable hemogram: platelet count < 75,000/ulXx_NEWLINE_xXPlatelet count >= 75,000/mm^3 without transfusion support > 7 days prior to registrationXx_NEWLINE_xXPlatelets >= 75,000/mcl (in the absence of platelet transfusion for >= 14 days)Xx_NEWLINE_xXPlatelets >= 75,000 cells/uLXx_NEWLINE_xXPlatelets < 75,000/uLXx_NEWLINE_xXPlatelet counts ?75,000/mm3 (?75×109/L)Xx_NEWLINE_xXPlatelet count >= 75,000/mm^3Xx_NEWLINE_xXPlatelets >= 75 X 10^9/LXx_NEWLINE_xXPlatelets > 75,000/mcLXx_NEWLINE_xXPlatelets <75 x 109/LXx_NEWLINE_xXPlatelet count <75,000/mcL.Xx_NEWLINE_xX